Catalyst event

Sanofi (SNY)

From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)

Sanofi announced that MenQuadfi received EU approval for active immunization against invasive meningococcal disease in infants from six weeks of age.

Korean translation

사노피가 생후 6주 이상 영아의 침습성 수막구균 질환 예방을 위한 MenQuadfi의 EU 승인을 발표함.